Virtual Library

Start Your Search

Zhongtai Wang

Author of

  • +

    P1.15 - Treatment in the Real World - Support, Survivorship, Systems Research (Not CME Accredited Session) (ID 947)

    • Event: WCLC 2018
    • Type: Poster Viewing in the Exhibit Hall
    • Track:
    • Presentations: 1
    • Moderators:
    • Coordinates: 9/24/2018, 16:45 - 18:00, Exhibit Hall
    • +

      P1.15-35 - Real World Outcome of Different Administrations Endostar Combined With Chemotherapy in Driver Gene Mutation Negative Advanced NSCLC (ID 12320)

      16:45 - 18:00  |  Author(s): Zhongtai Wang

      • Abstract


      To compare the efficacy and safety of different administration endostar combined with platinum-based chemotherapy with first-line treatment of driver gene mutation negative advanced NSCLC patients, and provides real-world evidence for optimum administration of endostar.

      a9ded1e5ce5d75814730bb4caaf49419 Method

      From April 2014 to April 2017, 88 driver gene mutation negative patients who received platinum-based chemotherapy alone or combined with endostar were retrospectively enrolled in this project. All the patients were divided to three groups, including platinum-based chemotherapy alone (arm A), combined with 14 days endostar (7.5 mg/m2, d1-14, q21d, arm B) and 7 days endostar (15 mg/m2, d1-7, q21d, arm C). The primary endpoint was median overall survival (OS). The secondary endpoints were median progression-free survival (PFS), objective response rate (ORR), and disease control rate (DCR). The efficacy and safety was evaluated every 2 cycles.

      4c3880bb027f159e801041b1021e88e8 Result

      Of all the 88 enrolled patients, the median OS was 20 months in endostar groups (arm B and arm C) and 10 months in chemotherapy alone group (arm A, P<0.001). The median PFS was months and 4.5 months respectively (P=0.073). The median OS was 22 months (arm B) and 14 months (arm C, P = 0.01). The median PFS was 6 months in arm B, 6.5 months in arm C, and 4.5 months in arm A. The ORR were 44.4%, 22.2% and 20.6% for arm B (P=0.046), arm C (P=0.877) and arm A respectively. The DCR were 88.9%, 77.8% and 64.7% for arm B (P=0.046), arm C (P=0.266) and arm A respectively. There is no meaningful difference in OS between arm B and arm C (P=0.111), as well as ORR (P=0.074) and DCR (P=0.234), but a meaningful difference in PFS (P=0.044). The incidence of adverse event in the three groups was 22.2%, 3.7%, and 11.6%, respectively. There was no new occurring intolerant adverse event.

      8eea62084ca7e541d918e823422bd82e Conclusion

      Endostar plus platinum-based doublet chemotherapy can significantly improve short-term and long-term outcomes in driver gene mutation negative advanced NSCLC. The administration of 14 days endostar compared to 7 days has no significant improvement in efficacy, but results in a higher incidence of adverse events.